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The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a global initiative intended
to improve drug proarrhythmia risk assessment using a new paradigm of mechanistic
assays. Under the CiPA paradigm, the relative risk of drug-induced Torsade de Pointes
(TdP) is assessed using an in silico model of the human ventricular action potential (AP)
that integrates in vitro pharmacology data from multiple ion channels. Thus, modeling
predictions of cardiac risk liability will depend critically on the variability in pharmacology
data, and uncertainty quantification (UQ) must comprise an essential component of the
in silico assay. This study explores UQ methods that may be incorporated into the
CiPA framework. Recently, we proposed a promising in silico TdP risk metric (qNet),
which is derived from AP simulations and allows separation of a set of CiPA training
compounds into Low, Intermediate, and High TdP risk categories. The purpose of
this study was to use UQ to evaluate the robustness of TdP risk separation by qNet.
Uncertainty in the model parameters used to describe drug binding and ionic current
block was estimated using the non-parametric bootstrap method and a Bayesian
inference approach. Uncertainty was then propagated through AP simulations to quantify
uncertainty in qNet for each drug. UQ revealed lower uncertainty and more accurate TdP
risk stratification by qNet when simulations were run at concentrations below 5× the
maximum therapeutic exposure (Cmax). However, when drug effects were extrapolated
above 10× Cmax, UQ showed that qNet could no longer clearly separate drugs by
TdP risk. This was because for most of the pharmacology data, the amount of current
block measured was <60%, preventing reliable estimation of IC50-values. The results of
this study demonstrate that the accuracy of TdP risk prediction depends both on the
intrinsic variability in ion channel pharmacology data as well as on experimental design
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considerations that preclude an accurate determination of drug IC50-values in vitro.
Thus, we demonstrate that UQ provides valuable information about in silico modeling
predictions that can inform future proarrhythmic risk evaluation of drugs under the CiPA
paradigm.
Keywords: uncertainty quantification, experimental variability, cardiac electrophysiology, action potential, Torsade
de Pointes, ion channel, pharmacology, computational modeling
INTRODUCTION
Drugs that block cardiac ion channels encoded by the human-
ether-à-go-go Related Gene (hERG) and consequently prolong
the QT interval are associated with increased risk of Torsade
de Pointes (TdP), a potentially lethal arrhythmia that caused
several drugs to be withdrawn frommarket (Gintant et al., 2016).
In 2005, the International Council on Harmonisation (ICH)
S7B and E14 guidelines were established to address the issue
of TdP liability for new drugs. As stated in these guidelines,
their intent was to be used as a screening method to identify
drugs that would require more intensive electrocardiographic
monitoring of patients in late phase (e.g., phase 3) clinical trials.
However, hERG block or QT prolongation does not necessarily
correlate with TdP risk, and as a result of these guidelines,
many novel compounds are screened out of development
because of detected hERG block or QT prolongation without
further evaluation of actual TdP risk. Additional insight into
TdP risk for hERG-blocking and QT-prolonging drugs can
be determined by also assessing whether drugs block inward
currents such as, L-type calcium or late sodium (Duff et al.,
1987; January and Riddle, 1989; Chézalviel-Guilbert et al., 1995;
Guo et al., 2007). The Comprehensive in vitro Proarrhythmia
Assay (CiPA) is a global initiative to revise the current
guidelines with a new set of mechanistic assays that improve the
specificity of the proarrhythmia screening process (Fermini et al.,
2016).
The CiPA in silico assay will test new compounds for the
potential to cause TdP by incorporating in vitro pharmacology
data on multiple ion channels into a mathematical model of the
cardiac action potential (AP). The AP model will be used to
predict drug effects related to early afterdepolarizations (EADs),
which are a known cellular trigger of TdP (Yan et al., 2001).
Numerous studies have shown that when outward repolarizing
currents such as, IKr (the current carried by hERG-encoded
channels) are blocked in cardiac cells, the resulting imbalance
of inward and outward currents prolongs the AP and can, at
extreme levels, lead to inward current reactivation and EADs
(January and Moscucci, 1992). However, EADs may not occur
if a drug also significantly blocks inward currents, leading
to a balanced block scenario where the AP is prolonged but
inward currents cannot reactivate (Antzelevitch et al., 2004).
Because it is difficult to know how much inward vs. outward
current block is safe, or how dynamic effects might impact
EAD propensity, the purpose of the CiPA in silico model will
be to assess the integrated effects of multiple ion channel block
on TdP risk. As with any model built on inherently variable
experimental data, however, confidence in model predictions
will depend on the level of uncertainty in model inputs (here,
the drug-specific parameters) and the corresponding uncertainty
in model outputs (Pathmanathan et al., 2015; Johnstone et al.,
2016b). In order for CiPA to provide useful guidance to the
drug development and regulatory process, it will be necessary
to incorporate uncertainty quantification (UQ) into modeling
predictions (Pathmanathan and Gray, 2013; Mirams et al.,
2016).
The CiPA in silico ventricular AP model and a mechanism-
based metric for TdP risk stratification have been trained on
a designated set of 12 CiPA compounds with known TdP
risk levels (High, Intermediate, or Low, see Table 1). These
compounds were selected and categorized by a team of expert
clinicians, safety pharmacologists, and electrophysiologists based
on adverse event data and published reports (Colatsky et al.,
2016). The current CiPA AP model was developed through
a series of modifications to the O’Hara-Rudy (ORd) human
ventricular AP model (O’Hara et al., 2011). Li et al. (2016) first
developed a Markov model of the hERG channel that included
temperature-sensitive gating, which was subsequently modified
to recapitulate IKr from the original ORd model, with an added
pharamacological component (Li et al., 2017). The hERG/IKr
model was then incorporated into the ORd AP model to produce
the IKr-dynamic ORd model. In the CiPAORdv1.0 model, we
further optimized the IKr-dynamic ORd model by scaling ionic
current conductances to better reflect changes in AP duration
observed in human ventricular myocytes when ionic currents
were blocked (referred to as the optimized IKr-dynamic ORd
model in Dutta et al., 2017). With this model, we derived a
new in silico biomarker for TdP risk, the qNet metric, which
correlated well with in silico cell “distance” to EADs and thus
provided a continuous marker for EAD susceptibility. Although
we showed that the qNet metric could correctly stratify the 12
CiPA training drugs by known TdP risk, uncertainty in these
modeling predictions was not evaluated.
In this study, methods for applying UQ to the CiPA in silico
assay are presented. For the 12 CiPA training compounds, we
examine the uncertainty in drug-specific kinetics parameters
for drug binding and trapping in the IKr-dynamic model. In
addition, we examine uncertainty in dose-response curve IC50
and Hill coefficients for the remaining six CiPA-selected ionic
currents, as this can also be considerable (Elkins et al., 2013).
We thereby characterize uncertainty in drug effects on ion
channels due to variation in experiments, whatever the cause of
this variation may be. We then sample from these probability
distributions for the drug effects and run forward simulations
to examine the subsequent uncertainty in qNet and TdP risk
stratification.
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TABLE 1 | TdP risk levels for the 12 CiPA training compounds.
Drug CiPA TdP Risk
Dofetilide High
Bepridil High
Sotalol High
Quinidine High
Cisapride Intermediate
Terfenadine Intermediate
Ondansetron Intermediate
Chlorpromazine Intermediate
Verapamil Low
Ranolazine Low
Mexiletine Low
Diltiazem Low
MATERIALS AND METHODS
Human Ventricular Action Potential Model
The CiPAORdv1.0 model (the optimized model fromDutta et al.,
2017) was used for all simulations in this study, in order to
evaluate TdP risk for the set of 12 CiPA training compounds
listed in Table 1. Parameter values for the model are listed in
Tables S1, S2.
Multiple Ion Channel Pharmacology
Pharmacological effects of the 12 CiPA training compounds on
ionic currents were modeled as in Li et al. (2017) and Dutta et al.
(2017). The kinetics of hERG block were modeled with the IKr
Markov model from Li et al. (2017), which was fit to voltage
clamp data obtained at the U.S. Food and Drug Administration
(FDA; parameters listed in Table 2). For six other ionic currents
(L-type calcium, ICaL; late sodium, INaL; fast sodium, INa;
transient outward, Ito; slowly activating delayed rectifier, IKs; and
inward rectifier, IK1), drug effects were represented by a simple
pore blocking model in which maximal current conductances
were reduced according to the Hill equation. Hill equation
parameters (Table 3) were fit to data from Crumb et al. (2016).
Some of the data have been updated since publication and are
available online (see section Software and Data).
Numerical Methods and Data Analysis
Model equations were written in C and compiled for use with
version 3.3 of the R programming language (R Core Team, 2016)
and version 1.14 of the deSolve package (Soetaert et al., 2010).
Equations were integrated using the lsoda solver with relative
and absolute error tolerances of 10−6 and other solver settings
as default. For computationally intensive bootstrap simulations
(see section Drug-hERG Binding Kinetics), a relative tolerance
of 10−3 was used. Data analysis was performed in R, and
figures were produced with version 2.2.0 of the ggplot2 package
(Wickham, 2009).
Simulation Protocol for TdP Risk
Evaluation
The CiPAORdv1.0 model was used to simulate APs at a cycle
length (CL) of 2 s (stimulus amplitude = −80 µA/µF, duration
= 0.5ms). The model was initialized from control (no drug)
steady-state values (Table S3) and paced for 1,000 beats. Drugs
were simulated at multiples of their maximum therapeutic
concentrations (Cmax, Table S4), ranging from 1 to 10× Cmax
(1× increments) and from 15 to 25× Cmax (5× increments).
At each concentration, TdP risk was evaluated using the metric
qNet, defined as the net charge carried by six major currents (IKr,
ICaL, INaL, Ito, IKs, and IK1) over an entire beat (Dutta et al., 2017).
The qNet metric was computed by integrating the sum of the six
currents from the start of the stimulus (t = 0 s) until the end of
the beat (t = 2 s) using lsoda (see sectionNumerical Methods and
Data Analysis).
Analysis was performed only on the last 250 beats of the
pacing protocol to allow drug effects to reach quasi-steady state
for simulations with beat-to-beat instability. Beats in which
transmembrane potential (Vm) failed to depolarize above 0mV
were excluded from analysis, and simulations in which every beat
failed to depolarize were excluded from TdP risk evaluation. The
maximum slope during repolarization (dV/dtrepol) was defined
as the maximum change in Vm (dV/dt) between 30 and 90%
repolarization for beats that fully repolarized; as the maximum
dV/dt between 30% repolarization and the end of the beat (t
= 2 s) when Vm repolarized by 30% but not 90%; or as the
maximum dV/dt between the AP peak and the end of the beat
when Vm failed to repolarize by 30%. An EAD was defined
to have occurred on any beat in which dV/dtrepol was greater
than zero. Out of the last 250 beats, the beat with the steepest
reactivation of the membrane potential (maximum dV/dtrepol)
was used to calculate qNet, whether or not an EAD had occurred.
Uncertainty Characterization
Drug-hERG Binding Kinetics
In Li et al. (2017), time series measurements of the fractional
hERG current in the presence of drug were obtained using a
modified Milnes voltage clamp protocol (Milnes et al., 2010; Li
et al., 2017). Because of the long duration of the protocol, each
cell could only be tested at a single drug concentration, and the
drug-hERG binding and trapping parameters (see Table 2) were
fit to the fractional current traces measured during a voltage
step to 0mV, averaged across cells by concentration. Specifically,
each dataset y consisted of a set of fractional current time series
observations xc,i(t) (c = 1, 2, . . . ,m, where m is number of the
concentrations tested; i = 1, 2, . . . , nc, where nc is the number of
cells tested at the cth concentration; and xc,i(tj) were independent
between concentrations). The mean drug response at the cth
concentration was x¯c (t) =
1
nc
∑nc
i=1 xc,i (t) (i.e., the average
of fractional current traces across cells), and the overall mean
response y¯ =
(
x¯1 (t) , x¯2 (t) , . . . , x¯m (t)
)
(i.e., the set of average
fractional current traces at each concentration) was used to fit
the optimal drug-hERG kinetics parameters (θˆ(y¯)). Parameters
were fitted using the Covariance Matrix Adaptation Evolutionary
Strategy (CMA-ES) (Hansen, 2006), with version 1.0-11 of the
cmaes package (Trautmann et al., 2011). Details on the CMA-
ES implementation can be found in the Supplemental Methods.
Bounds for the dynamic drug-hERG binding parameters used to
fit bootstrap samples can be found in Table S5.
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TABLE 2 | Drug-hERG binding parameters for the 12 CiPA training compounds.
log10(Kmax) log10(EC50
n) log10(Kmax/EC50n)
Dofetilide 1.5453 [0.9209, 6.8153] 2.3357 [1.7982, 7.5726] −0.7905 [−1.0125, −0.6304]
Bepridil 6.7477 [5.4278, 7.1407] 8.1679 [6.803, 8.5243] −1.4202 [−1.7124, −1.1736]
Sotalol 4.9831 [0.8193, 5.4306] 8.5861 [4.965, 8.9975] −3.6029 [−4.5017, −3.1522]
Quinidine 2.4404 [1.1871, 6.4189] 4.731 [3.6678, 8.7601] −2.2906 [−2.7484, −2.0986]
Cisapride 1.0095 [0.839, 1.6553] 1.6265 [1.4211, 2.2125] −0.6171 [−0.9699, −0.4154]
Terfenadine 5.0095 [1.2953, 6.2265] 5.6123 [1.8881, 6.8917] −0.6028 [−0.7791, −0.4311]
Ondansetron 5.2355 [1.5791, 6.3269] 7.718 [4.341, 8.7997] −2.4825 [−2.7992, −2.2702]
Chlorpromazine 5.1984 [4.696, 6.5012] 7.6386 [7.0863, 8.9725] −2.4402 [−2.7268, −2.2162]
Verapamil 6.2289 [1.5379, 6.803] 8.5258 [4.1385, 8.9922] −2.2969 [−2.9551, −1.7767]
Ranolazine 1.723 [1.3627, 5.6536] 5.1553 [4.8122, 8.7298] −3.4324 [−4.0139, −2.9363]
Mexiletine 1.1761 [1.0208, 1.497] 5.8591 [5.3159, 6.5914] −4.683 [−5.5154, −3.9582]
Diltiazem 5.2613 [1.6549, 5.6663] 8.8246 [5.7087, 8.9997] −3.5634 [−4.1562, −3.223]
n log10(Ku) Vhalftrap
Dofetilide 1.08 [0.9527, 1.467] −4.7409 [−4.9767, −4.6633] −1 [−26.01, −1]
Bepridil 0.9374 [0.8227, 1.074] −3.7647 [−3.8713, −3.671] −61.34 [−72.94, −18.36]
Sotalol 0.7513 [0.6594, 0.955] −1.6527 [−2.0183, −0.4512] −51.5 [−74.62, −7.756]
Quinidine 0.8488 [0.7775, 1.028] −2.3869 [−2.3649, −1.7435] −61.35 [−72.31, −5.445]
Cisapride 0.9615 [0.5928, 1.372] −3.3808 [−3.4836, −3.2553] −167.4 [−190.3, −156.5]
Terfenadine 0.6502 [0.5033, 0.7918] −4.1086 [−4.2938, −4.0023] −81.63 [−155, −73.87]
Ondansetron 0.891 [0.83, 1.002] −1.6338 [−1.7335, −1.3971] −82.2 [−88.69, −77.64]
Chlorpromazine 0.8871 [0.8006, 0.9916] −1.3306 [−1.7312, −0.7396] −14.45 [−66.29, −2.865]
Verapamil 1.043 [0.832, 1.317] −3.088 [−3.1708, −2.6366] −97.08 [−192, −85.3]
Ranolazine 0.9532 [0.8248, 1.106] −1.6914 [−1.914, −0.0004] −94.99 [−176.4, −81.16]
Mexiletine 1.139 [0.956, 1.34] −1.1479 [−1.4011, −0.016] −87.51 [−164.8, −77.68]
Diltiazem 0.9382 [0.8612, 1.086] −0.5498 [−1.0751, 0] −90.65 [−180.3, −81.18]
The optimal values are shown with 95% CIs obtained with bootstrapping. Units are as follows: Kmax (unitless), Ku (ms
−1 ), EC50 (nM), n (unitless), and Vhalftrap (mV).
The non-parametric bootstrap method was used to
characterize uncertainty in the fitted parameters (Efron and
Tibshirani, 1986). Observations x∗c,i(t) were randomly drawn
with replacement from xc,i(t) to obtain a bootstrap sample y
∗
b
of
the same size as the original dataset, with an identical number
of observations per concentration. A total of 2,000 bootstrap
samples (b = 1, 2, . . . , 2000) were generated using version 1.3-18
of the boot package (Davison and Hinkley, 1997; Canty and
Ripley, 2016). The mean response y¯
∗
b for each bootstrap sample
was then computed in the same manner as y¯ and used to refit
the drug-hERG kinetics parameters (θˆ(y¯
∗
b)), yielding a joint
sampling distribution of drug-hERG parameters.
Dose-Response Curves
For other ionic currents, uncertainty in dose-response curves was
characterized using a Bayesian inference approach. Version 1.3.5
of the FME package was used to fit Hill equation parameters
and to characterize uncertainty, using Markov-chain Monte
Carlo (MCMC) simulation with the delayed rejection and
adaptive Metropolis algorithm (Soetaert and Petzoldt, 2010).
The percentage of ionic current block was assumed to be a
normal random variable located at the Hill equation response
curve with unknown variance σ 2. Log-transformed IC50-values
[pIC50 =−log10(IC50/c0), where c0 = 10
9 nM] were bounded to
the range [−1, 19] for fitting and MCMC simulation (bounding
IC50-values between 10
−10 and 1010 nM). Hill coefficients (h)
were bounded to the range [0, 10]. Optimal IC50 and Hill
coefficient (h)-values were fit using non-linear least squares (see
Table 3). The joint probability distribution of IC50 and h was
estimated usingMCMC simulation. A uniform prior distribution
was used for pIC50 and h. The error variance σ
2 was considered
a nuisance parameter and was sampled as conjugate priors
from an inverse gamma distribution during MCMC simulation.
The proposal distribution was multivariate normal. A total of
2,000 MCMC samples (pIC50, h) were saved for each drug-
current combination to form a joint sampling distribution
of Hill equation parameters (see Supplemental Methods for
implementation details).
Credible Intervals
Variability of model inputs (parameters) or outputs (predicted
responses) was summarized with 95% credible intervals (95%
CIs, the 2.5–97.5% quantiles of the marginal distributions).
Uncertainty Propagation
Samples from the joint distribution of drug-hERG parameters
and the joint distributions of Hill equation parameters for a
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TABLE 3 | Hill equation parameters for the 12 CiPA training compounds.
ICaL IK1 IKs
Dofetilide pIC50 6.5845 [−0.7468, 7.9108] 6.4041 [−0.7384, 7.8736] N/A
h 1.163 [0.32, 9.622] 0.765 [0.2685, 9.658] N/A
Cisapride pIC50 2.0331 [−0.8172, 6.4905] 4.5305 [−0.7411, 6.7042] 1.0906 [−0.767, 6.528]
h 0.4261 [0.4063, 9.736] 0.5133 [0.2572, 9.63] 0.2921 [0.2409, 9.67]
Bepridil pIC50 5.5516 [5.2752, 5.71] N/A 4.5432 [3.4422, 4.9682]
h 0.6486 [0.4351, 0.9191] N/A 0.7061 [0.3907, 1.142]
Verapamil pIC50 6.6951 [6.6029, 6.7891] 0.4574 [−0.8155, 5.7514] N/A
h 1.097 [0.861, 1.43] 0.2728 [0.2526, 9.655] N/A
Terfenadine pIC50 6.1547 [6.0876, 6.2131] N/A 3.3982 [0.0077, 5.9477]
h 0.6601 [0.595, 0.7367] N/A 0.543 [0.2777, 9.728]
Ranolazine pIC50 N/A N/A 1.4418 [−0.624, 4.3335]
h N/A N/A 0.5191 [0.3292, 8.066]
Sotalol pIC50 2.1511 [1.7907, 2.3628] 2.5157 [2.385, 2.5955] 2.3745 [2.0951, 2.507]
h 0.8651 [0.5902, 1.259] 1.204 [0.9066, 1.611] 1.167 [0.7741, 1.698]
Mexiletine pIC50 4.4175 [3.9423, 4.6525] N/A N/A
h 1.031 [0.6484, 1.576] N/A N/A
Quinidine pIC50 4.2874 [3.8501, 4.5293] 1.4024 [−0.7594, 5.0793] 5.3099 [5.2008, 5.3813]
h 0.5892 [0.4384, 0.7362] 0.3468 [0.2715, 9.492] 1.363 [0.9565, 2.122]
Ondansetron pIC50 4.6469 [4.4138, 4.7937] N/A 3.2443 [2.138, 3.9253]
h 0.7526 [0.5478, 1.024] N/A 0.6535 [0.3954, 1.238]
Diltiazem pIC50 6.9504 [6.7786, 7.1267] N/A N/A
h 0.7142 [0.5344, 1.008] N/A N/A
Chlorpromazine pIC50 5.0866 [4.9108, 5.2128] 5.0329 [4.8446, 5.1718] N/A
h 0.8441 [0.6105, 1.189] 0.6878 [0.5226, 0.8822] N/A
Ito INaL INa
Dofetilide pIC50 7.7254 [6.8317, 7.9571] 3.1231 [−0.754, 7.8227] 6.4196 [−0.6142, 8.0307]
h 0.7712 [0.3735, 1.147] 0.2597 [0.1543, 9.49] 0.892 [0.2235, 9.497]
Cisapride pIC50 3.6594 [−0.6456, 5.6778] N/A N/A
h 0.243 [0.1166, 0.5656] N/A N/A
Bepridil pIC50 5.0658 [−0.5052, 5.3383] 5.7414 [5.6743, 5.8074] 5.5333 [5.3948, 5.6158]
h 3.541 [0.4166, 9.499] 1.416 [1.133, 1.789] 1.164 [0.8083, 1.71]
Verapamil pIC50 4.8719 [1.1464, 5.5056] 5.1532 [−0.6313, 5.8804] N/A
h 0.8222 [0.2414, 1.793] 1.031 [0.222, 9.41] N/A
Terfenadine pIC50 3.6198 [−0.0501, 5.1184] 4.6977 [2.6363, 5.8293] 5.3185 [4.8576, 6.0114]
h 0.2559 [0.1246, 0.5777] 0.6011 [0.269, 3.232] 1.015 [0.6554, 9.176]
Ranolazine pIC50 N/A 5.1033 [4.9859, 5.2079] 4.1626 [3.2696, 4.5616]
h N/A 0.945 [0.7247, 1.256] 1.425 [0.6228, 9.116]
Sotalol pIC50 1.3651 [−0.3529, 2.1817] N/A −0.0584 [−0.8951, 2.4926]
h 0.6632 [0.3213, 1.704] N/A 0.5089 [0.3913, 8.449]
Mexiletine pIC50 N/A 5.0478 [4.9484, 5.1128] N/A
h N/A 1.409 [1.041, 1.846] N/A
Quinidine pIC50 5.4575 [5.3999, 5.511] 5.0261 [4.9062, 5.1077] 4.909 [4.6683, 5.0426]
h 1.282 [1.049, 1.585] 1.337 [1.034, 1.7] 1.494 [1.004, 2.236]
Ondansetron pIC50 2.9901 [−0.8308, 4.4636] 4.7172 [4.6073, 4.8] 4.2391 [3.5217, 4.6469]
h 0.9891 [0.4407, 9.691] 1.035 [0.8001, 1.399] 1.02 [0.5024, 8.671]
Diltiazem pIC50 −0.4506 [−0.922, 2.6212] 4.6602 [4.5116, 4.7776] 3.9551 [3.2876, 4.8315]
h 0.1696 [0.1551, 0.364] 0.6779 [0.5485, 0.9082] 0.7022 [0.4484, 9.337]
Chlorpromazine pIC50 1.754 [−0.6914, 4.776] 5.341 [5.2543, 5.4232] 5.3433 [5.221, 5.4298]
h 0.3654 [0.2318, 8.56] 0.9379 [0.7797, 1.148] 1.995 [1.628, 3.064]
The optimal fitted values are shown with 95% CIs obtained using Markov-chain Monte Carlo simulation. IC50-values are log-transformed as pIC50 = −log10(IC50/c0), where c0 = 10
9
nM. Not applicable (N/A) indicates that IC50-values were not defined in Li et al. (2017), so the amount of block was assumed to always be 0%.
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particular drug were assumed to be independent and were
combined in AP simulations to assess the uncertainty in qNet
(see section Simulation Protocol for TdP Risk Evaluation). One
sample from each distribution was selected in sequential order
(e.g., the first sample from each distribution) to form a set of
parameters that defined a single sample from the drug-effect
probability distribution. This was repeated until all parameter
samples were exhausted, generating a sampling distribution of
2,000 drug-effect samples per drug (referred to as uncertainty
inputs), which. Each input was simulated with the CiPAORdv1.0
model to assess variability in APmodel outputs (qNet, see section
Simulation Protocol for TdP Risk Evaluation). Variability in qNet
was quantified with 95%CIs. Sampling distributions of qNet were
visualized with violin plots.
Cross Validation
Leave-one-out cross validation (LOOCV) (Hastie et al., 2009)
was used to assess the accuracy of TdP risk stratification at
each simulated concentration relative to Cmax. The CiPA Low,
Intermediate, and High TdP risk levels (Table 1) were given
numerical category values of 0, 1, and 2, respectively. At each
concentration (1−25× Cmax), a classifier was trained on all
samples from the qNet distributions of all but one of the training
drugs. The classifier was based on proportional odds logistic
regression using the lrm function from version 4.5-0 of the rms
package (Harrell, 2016). The numerical tolerance was set to 10−10
and the maximum number of iterations was set to 106 for fitting.
Each sample of the remaining, “left out” drug was then assigned
to the category with the highest probability based on logistic
regression results. The predicted probability of each category
[P(x), where x is 0, 1, or 2] for the “left out” drug was computed
as the fraction of samples assigned to that category, and the
prediction error for that drug was computed as themean absolute
difference between the assigned and actual TdP category over all
samples. This procedure was repeated for all 12 training drugs,
and the mean and standard deviation of prediction errors at
each concentration were computed to evaluate overall TdP risk
stratification performance.
Software and Data
The software and data used in this study are available at https://
github.com/FDA/CiPA.
RESULTS
Uncertainty in Drug-hERG Binding Kinetics
Bootstrapping was performed with voltage clamp data from
Li et al. (2017) in order to estimate the joint probability
distribution of fitted drug-hERG dynamic binding parameters.
The 95% CIs of hERG binding parameters for the 12 CiPA
training drugs (Table 1) are listed in Table 2. Parameter fitting
results for bepridil are illustrated in Figure 1A. The rate
of bepridil unbinding (Ku) had a relatively narrow 95% CI
[10−3.8713, 10−3.671 ms−1], indicating that this parameter was
well-constrained by the experimental data and uncertainty in its
value was low. In contrast, the pairwise scatter plot of log10(Kmax)
and log10(EC50
n) revealed a strong correlation between the
two parameters, and their fitted ranges spanned several orders
of magnitude. The pairwise scatter plots for other training
drugs displayed similar correlations between log10(Kmax) and
log10(EC50
n) (panel A in Figures S1–S11).
The large uncertainty in Kmax and EC50
n did not produce
a similar degree of variability in the kinetics of hERG block,
however. In Figure 1B and panel B of Figures S1–S11, shaded
areas indicate the 95% CI of the block predicted by parameters
in Figure 1A and panel A of Figures S1–S11. The variability
in hERG block was much more limited than the variability in
Kmax or EC50
n, which was not surprising because Li et al. (2017)
showed that for most of the 12 training drugs, there was a
near-linear relationship between drug concentration and binding
rate, occurring when the fitted EC50-value was much greater
than the maximum drug concentration tested. For example, the
optimal EC50-value of bepridil was 10
8.7 nM, and the bootstrap-
estimated 95% CI was [107.0, 109.7], but the maximum bepridil
concentration tested was 300 nM, or roughly 102.5 nM. In such
cases, the Emax equation defining the sigmoidal dose-response
relationship of drug binding [Emax = Kmax
∗(Dn/(Dn+EC50
n))]
was linearly approximated by Emax≈(Kmax/EC50
n)∗Dn, and
the ratio Kmax/EC50
n effectively becomes a single identifiable
parameter. Thus, the 95% CIs for log10(Kmax/EC50
n) were much
narrower than the 95% CIs for log10(Kmax) and log10(EC50
n)
(Table 2). The Emax equation was chosen to model drug binding
because of its flexibility in accommodating both linear and
sigmoidal dose-response relationships. As a result, for those
compounds whose drug binding mode is actually linear, the ratio
but not the individual values of the two correlated parameters
were identifiable (Li et al., 2017).
In addition, multimodality (the presence of multiple peaks
in the sampling distribution) was frequently observed in other
hERG kinetics parameters (Figures S1–S11), in particular with
Vhalftrap. In the hERG binding model, Vhalftrap is a drug trapping
parameter that determines the steady-state fraction of open-
bound (untrapped) to close-bound (trapped) channels. Li et al.
(2017) demonstrated that the High- and Low-risk CiPA training
drugs could be separated by this single parameter (Vhalftrap >
−65mV for High-risk drugs, while Vhalftrap < −85mV for Low-
risk drugs). The multimodality identified in Vhalftrap sampling
distributions raised the question of whether this trend still holds
under uncertainty analysis. As shown in Figure 2, the 95% CIs
of Vhalftrap were quite wide for most drugs, but much of this
variability covered ranges where the ratio of open- to close-bound
channels (Obound/Cbound) at −80mV was relatively flat, near 1
for Low-risk drugs (green bars) or near 0 for High-risk drugs
(red bars). In the steepest region of the Obound/Cbound curve,
Vhalftrap distributions of High- vs. Low-risk drugs were well-
separated (upper credible bounds<−77mV for Low-risk drugs,
lower credible bounds>−75mV forHigh-risk drugs). Thus, UQ
identified consistently low or high levels of trapping for Low- vs.
High-risk drugs, respectively, providing increased confidence in
the Vhalftrap trend identified by Li et al. (2017). Note that with
or without UQ, the Vhalftrap-values of Intermediate-risk drugs
(blue bars and points) other than chlorpromazine were generally
indistinguishable from Low-risk drugs, and chlorpromazine
was indistinguishable from High-risk drugs, indicating that the
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FIGURE 1 | Uncertainty in bepridil-hERG binding kinetics. (A) The joint probability distribution of Kmax (maximum drug effect at saturating concentrations), Ku (rate of
drug unbinding), n (Hill coefficient of drug binding), EC50
n (nth power of the half-maximal drug concentration), and Vhalftrap (drug trapping potential) was estimated by
bootstrapping. Plots on the diagonal show the marginal histograms of each parameter (log-transformed in some cases). Plots below the diagonal show pairwise
scatter plots of the fitted parameters for 2,000 bootstrap samples. (B) Kinetics of hERG block during 10 sweeps of a modified Milnes voltage-clamp protocol (Milnes
et al., 2010; Li et al., 2017). Shaded areas show the range of block produced by the parameters from (A). Lines show the experimental results used to fit the data
(down-sampled 5× for clarity).
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FIGURE 2 | Uncertainty in drug trapping for the 12 CiPA training drugs. Fitted
Vhalftrap-values (points) are plotted along the curve defining the resulting
steady-state fraction of open-bound to close-bound channels
(Obound/Cbound) at Vm = −80mV. The 95% CIs (horizontal error bars) were
estimated with bootstrapping. High TdP-risk drugs are in red, Intermediate-risk
drugs are in blue, and Low-risk drugs are in green. Intermediate-risk drugs
were indistinguishable from Low- and High-risk drugs.
degree of drug trapping is not sufficient to stratify compounds
into the three CiPA risk levels.
Uncertainty in Dose-Response Curves
Bayesian inference was used to estimate the joint probability
distribution of Hill equation parameters characterizing steady-
state INa, ICaL, INaL, Ito, IKs, and IK1 block by each of the 12
CiPA training drugs. MCMC simulation was not performed
for drug-current combinations that did not have defined IC50-
values in Li et al. (2017), which were assumed to have 0%
block. Parameter fitting results are summarized in Table 3. Some
MCMC simulations produced joint sampling distributions with
a single well-defined peak, such as, that of ranolazine-INaL
(Figure 3A). The mean parameter values of this distribution
(pIC50 = 5.0958, h = 0.9594) were close to the optimal
fitted values (pIC50 = 5.1033, h = 0.945), and the 95%
CIs [pIC50 (4.9859, 5.2079), h (0.7247, 1.256)] were relatively
narrow, indicating that uncertainty in these parameters was low.
Consequently, the variability in dose-response curves defined
by these parameters was also low. At any given concentration,
uncertainty in ranolazine-INaL block (i.e., the width of its 95%
CI) was<16% (Figure 3B, shaded area), reflecting the variability
observed in experiments (circles). Note that uncertainty in
ranolazine- INaL block did not increase at concentrations beyond
the highest tested (23µM) because the well-constrained dose-
response curve allowed for extrapolation beyond experimentally
tested concentrations.
For other MCMC simulations such as, dofetilide-INaL, an
inverse relationship of possible IC50- and h-values was observed,
without a defined peak (Figure 3C). Furthermore, many MCMC
samples reached near the bounds imposed on IC50 and h during
fitting [95% CIs for pIC50 (−0.754, 7.8227] and h [0.1543,
9.49)]. This was symptomatic of having insufficient experimental
data to constrain IC50-values, as the maximum measured INaL
block was 12.1% at 3× Cmax, the highest concentration tested
(Figure 3D, circles). Although an optimal fit could be defined
using least squares (solid line), confidence in the fitted parameters
was low, and uncertainty in predicted block increased abruptly
above 3× Cmax. At 10× and 25× Cmax, the 95% CIs of
predicted block were [0, 82.8%] and [0, 99.8%], respectively,
reaching close to the maximum possible range (shaded area).
Thus, under circumstances where insufficient current block
was achieved in experiments, uncertainty in the dose-response
relationship became very high when extrapolating beyond the
tested concentrations. Similar findings were obtained with other
drug-current combinations (Table 3 and Figures S12–S62).
The amount of uncertainty in predicted block (measured
as the width of the 95% CI) was examined as a function of
the mean block achieved at the highest tested concentration
(Chigh). Table 4 lists the mean block measured in experiments
at 1× Chigh for the 12 CiPA training drugs (some drugs had a
different Chigh for different channels). The resulting uncertainty
in the amount of drug block at concentrations above Chigh
is depicted in Figure 4. At 1× Chigh, uncertainty was <25%
for all drug-current combinations, indicating that variability in
the experimental observations was low. When uncertainty was
quantified at extrapolated concentrations (2×, 3×, and 10×
Chigh), differences were observed between experiments with
low and high amounts of block at 1× Chigh. When <30%
mean block was measured at 1× Chigh, uncertainty was >25%
for most dose-response curves and reached close to 100% in
several cases. But when >60% mean block was measured at
1× Chigh, uncertainty at the extrapolated concentrations was
<16%. Thus, UQ results for this dataset suggest that>60% block
should be achieved experimentally if dose-response curves are to
predict drug effects beyond the tested concentrations. Although
>60% block was achieved in hERG experiments with the 12
CiPA training drugs, none of the training drugs were tested
at concentrations producing >60% block for all six non-hERG
ionic currents (which would be unlikely other than for quinidine,
given the selectivity of these compounds). This analysis therefore
suggested that drug effects could only be reliably predicted at the
highest experimentally tested concentration for which data on all
six non-hERG ionic currents were available (Table 4).
Propagation of Uncertainty to AP
Simulations
Uncertainty in drug-hERG kinetics and dose-response curves
was propagated to AP simulations to explore its impact on
TdP risk stratification for the 12 CiPA training drugs. For each
drug, the optimal drug-hERG parameters and Hill equation
parameters (referred to as fixed inputs) were used to simulate
APs, as in previous studies (Dutta et al., 2017; Li et al., 2017).
In addition, a total of 2,000 drug-effect uncertainty samples
per drug (referred to as uncertainty inputs) were simulated
in order to estimate the distribution of drug effects derived
from uncertainty characterization (see section Uncertainty in
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FIGURE 3 | Uncertainty in the dose-response relationship of late sodium current (INaL ) block by ranolazine (A,B) and dofetilide (C,D). (A,C) show the joint distribution
of pIC50 and Hill coefficient (h)-values, estimated with a Bayesian inference approach. Marginal histograms are displayed on the diagonal plots, and pairwise scatter
plots are below the diagonal (2,000 samples per drug). IC50-values are in nM. (B,D) show the dose-response relationships for the two drugs. Solid lines show the Hill
equation defined by IC50- and h-values from Li et al. (2017). Shaded areas denote the 95% CI of the percentage block at each concentration, as determined by the
parameters in (A,C). Circles are the experimental values used to fit the dose-response curves. Vertical dotted lines indicate the limits of the concentration range used
in AP simulations (1−25× Cmax).
Drug-hERG Binding Kinetics–Uncertainty in Dose-Response
Curves). Individual beats were classified as having normal APs,
EADs, or depolarization failure (Figure 5A), and each simulation
was classified as having EADs, complete depolarization failure,
or normal otherwise (see section Simulation Protocol for TdP
Risk Evaluation). As drug concentration increased from 1 to
25× Cmax in uncertainty-input simulations, repolarization and
depolarization abnormalities became more frequent for some
training drugs. EADs occurred in quinidine, dofetilide, and
ranolazine simulations (Figure 5B), and depolarization failure
occurred in quinidine, dofetilide, ranolazine, and verapamil
simulations (Figure 5C). However, the frequency of these events
was generally low except in quinidine simulations, which had
EADs in>90% of simulations at 3–10× Cmax and depolarization
failure in >50% of simulations at ≥20× Cmax. While EADs are
mechanistically linked to TdP, depolarization failure constitutes a
different type of rhythm disturbance; therefore, simulations with
depolarization failure were removed from further analysis. The
remaining simulations represented the conditional distribution
of drug effects, given that depolarization failure did not occur at
a particular concentration.
Impact of Uncertainty on TdP Risk
Stratification
Although EADs are a mechanistic marker for TdP risk,
stratification based on EADs was not possible because they
occurred very rarely in simulations, and not at all for many
High Risk compounds at free Cmax. Instead, Dutta et al. (2017)
proposed to use the in silico metric qNet (the net charge carried
by major AP currents during one paced beat at steady state) as
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TABLE 4 | Mean current block at the highest drug concentrations tested in experiments (Chigh).
Drug Chigh × Cmax ICaL (%) IK1 (%) IKs (%) INa (%) INaL (%) Ito (%)
Dofetilide 6 nM 3 1.2 3.4 0.2 2.5 4.6 27.0
Bepridil 3 uM 90.9 50.7 0.5 16.2 51.7 67.0 2.4
Sotalol 2100 uM 143.0 26.0 38.6 30.6 3.9 11.0 11.4
Quinidine 5.4 uM 1.7 20.2 5.6 55.5 22.3 31.8 64.2
Cisapride 125 nM 48.1 0.7 5.3 1.8 2.4 0.0 13.2
Terfenadine 800 nM 200 52.0 0.0 3.3 14.0 12.7 20.6
Ondansetron 20 uM 143.9 47.4 3.0 9.9 25.5 51.6 2.0
Chlorpromazine 10.5 uM 276.3 55.4 51.1 5.2 84.2 69.2 6.0
Verapamil 1 uM 12.3 85.7 3.9 – 0.5 12.0 9.9
500 nM 6.2 – – 2.4 – – –
Ranolazine 23 uM 11.8 2.5 0.3 2.1 17.4 72.3 –
69 uM 35.4 – – – – – 26.5
Mexiletine 10 uM 2.4 19.5 0.6 0.0 6.1 51.9 1.0
Diltiazem 12.5 uM 102.5 97.0 4.6 0.0 17.7 40.6 11.0
Concentrations are also expressed as multiples of the maximum therapeutic concentration (× Cmax ). Because some ionic current experiments used different test concentrations,
verapamil and ranolazine both have two entries in the table.
FIGURE 4 | Uncertainty in dose-response curves at extrapolated drug concentrations. Current block experiments were performed for six ionic currents (see legend)
with the 12 CiPA training drugs (72 drug-current combinations total with 19 excluded, see Table 3). Dose-response curves were fitted for each experiment and
extrapolated above the highest experimentally tested drug concentration (Chigh). Uncertainty in dose-response curves was quantified at 1×, 2×, 3×, and 10× Chigh
as the width of the 95% CI for the predicted percentage block, plotted as a function of the mean experimentally observed block at 1× Chigh. Vertical dotted line is
drawn at 60% observed mean block, denoting an approximate lower limit on the mean block that was observed at 1× Chigh in experiments for which uncertainty
remained low (<16%) at higher concentrations.
an indicator of how far a cell is at a particular drug concentration
from producing an EAD. The qNetmetric was used in the present
study as a marker of TdP risk because it successfully stratified
the 12 CiPA training drugs at a range of concentrations in the
previous study by Dutta et al. (2017). The calculation of qNet
was updated to include simulations in which EADs occurred (see
section Simulation Protocol for TdP Risk Evaluation) so that
the sampling distributions of qNet would accurately reflect the
uncertainty in drug parameters (excluding those that produced
depolarization failure). As expected, the values of qNet obtained
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FIGURE 5 | Repolarization and depolarization abnormalities in AP simulations. (A) Traces showing representative examples of beats with normal APs (solid), EADs
(dashed), or depolarization failure (dotted). (B,C) The percentage of uncertainty-input simulations (2,000 total) in which EADs occurred (B) or which had complete
depolarization failure (C) is shown as a function of drug concentration in (B,C), respectively. Only results for drugs that had these events at the simulated
concentrations (1−25× Cmax) are plotted. (Note that ranolazine had 19 simulations with EADs at 25× Cmax; verapamil only had one instance of depolarization failure
occurring at 25× Cmax.) Markers indicate whether simulations with fixed inputs produced normal Aps (circles), EADs (triangles), or depolarization failure (squares).
with uncertainty-input simulations trended according to TdP
risk (Figures 6A,B). At a given concentration, median qNet-
values decreased between the Low, Intermediate, and High TdP-
risk drugs, indicating that outward currents were diminished and
inward currents became increasingly dominant at higher risk
levels. Note also that extreme negative values of qNet occurred
when EADs were present (Figure 6B), reflecting the higher TdP
risk evident in these simulations.
Variability in qNet increased as uncertainty in drug effects
increased. At 1× Cmax, the distribution of qNet-values for
each drug was relatively narrow, and as a result, only a small
amount of overlap was observed between adjacent TdP risk
levels (Figure 6A). At 10× Cmax, however, the distribution of
qNet-values for dofetilide (a High-risk drug) contained several
outliers, which encompassed the values for all other drugs except
the most negative quinidine values (Figure 6B). These outliers
resulted from the high degree of uncertainty in dose-response
curves for dofetilide above the highest concentration tested (3×
Cmax), particularly with inward currents. As discussed in section
Uncertainty in Dose-Response Curves, uncertainty in INaL block
by dofetilide increased dramatically above 3× Cmax (Figure 3D,
shaded area). A similar pattern occurred for ICaL block by
dofetilide (Figure S12), with high uncertainty in predicted block
at 10× Cmax [95% CI (0%, 97.6%)]. Because qNet reflects the
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FIGURE 6 | Uncertainty in qNet for the 12 CiPA training drugs. Violin plots are shown for qNet distributions at 1× (A) and 10× (B) Cmax, based on uncertainty-input
simulations. Dotted line indicates the control (no drug) value of qNet. (C) qNet at 1−10× Cmax (1× increments) and 15−25× Cmax (5× increments). Shaded areas
indicate the 95% CIs of qNet obtained from uncertainty-input simulations. Points indicate the highest simulated concentration for which complete experimental data
on six non-hERG currents were available. Fixed-input results are shown below (solid lines) or above (dotted lines) this concentration. Likewise, uncertainty-input results
are indicated below (dark shaded areas) or above (light shaded areas) this concentration. Simulations with depolarization failure (Figure 5B) were excluded from the
results. For all panels, High TdP-risk drugs are in red, Intermediate-risk drugs are in blue, and Low-risk drugs are in green.
balance of inward currents (INaL and ICaL) and outward currents
(mainly IKr), the effects of IKr block by dofetilide were offset in
simulations with significant block of INaL or ICaL, resulting in the
“safe” outliers for dofetilide at 10× Cmax with very high qNet-
values. On the other hand, simulations with very little INaL or
ICaL block led to “dangerous” outliers with very low or negative
qNet-values.
Poor separation of qNet between TdP risk levels was apparent
at higher drug concentrations, due primarily to the increased
uncertainty in drug effects. Dutta et al. (2017) showed that with
fixed model simulations, perfect separation in qNet occurred for
the 12 CiPA training drugs at 1–25×Cmax. However, our analysis
of dose-response uncertainty in section Uncertainty in Dose-
Response Curves suggests that qNet may be highly variable above
experimentally tested concentrations. In Figure 6C, fixed-input
simulation results are shown for concentrations up to (solid lines)
and including (point) the maximum simulated concentrations
for which complete drug block data on all six non-hERG ionic
currents was available; above these concentrations, fixed-input
results are plotted as dotted lines. At 1×Cmax, data were available
for all 12 CiPA training drugs. Above 1× Cmax, however, some
data were unavailable for quinidine (>1.7× Cmax), mexiletine
(>2.4× Cmax), dofetilide (>3× Cmax), verapamil (>6.2× Cmax),
and ranolazine (>11.8× Cmax; see Table 4). Nevertheless, near
1× Cmax, the 95% CIs of qNet remained largely separated
between TdP risk levels, indicating that uncertainty at these
concentrations was low enough to stratify the training drugs
(shaded areas). At>4×Cmax, however, overlap between different
risk levels increased due to the higher variability in qNet
sampling distributions, particularly for verapamil and dofetilide.
However, increased uncertainty in qNet was not the sole factor
affecting TdP risk separation. The qNet-values for verapamil
and ranolazine (Low-risk drugs) also drifted closer to those
of chlorpromazine (Intermediate-risk) at >4× Cmax, further
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increasing the overlap between these risk levels, though qNet-
values for fixed-input results remained separate.
The accuracy of TdP risk stratification as a function of
concentration was assessed using LOOCV. At each concentration
relative to Cmax, a classifier was trained on qNet uncertainty
samples for 11 of the 12 training drugs and then used to
predict the probabilities of each TdP risk level for the remaining
drug (see section Cross Validation). At 1× Cmax, the maximum
probability always occurred at the correct TdP risk level, but
several drugs had non-zero probabilities for the incorrect TdP
risk level (Table 5). In contrast, when LOOCV was performed
at 1× Cmax in Dutta et al. (2017), two drugs (terfenadine
and chlorpromazine) were misclassified on the basis of fixed-
input results (equivalent to a predicted 100% probability of
the drug being in the wrong category). As a result, although
LOOCV prediction errors were non-zero for more drugs when
uncertainty was considered, the overall mean prediction error
was lower as compared to fixed-input results (0.09 vs. 0.17). At
10× Cmax, however, mean prediction error was higher when
the classifier was trained on uncertainty-input results rather
than fixed-input results (0.23 vs. 0.08) because of increased
prediction errors for dofetilide, sotalol, cisapride, and verapamil.
This was due to the low level of block achieved experimentally
for many non-hERG currents, which led to high uncertainty
in qNet when drug effects were extrapolated above the tested
concentrations. Thus, uncertainty analysis producedmore robust
TdP risk predictions near concentrations with experimental data
for all currents but less robust predictions at concentrations
for which extrapolation of drug effects was unreliable due to
insufficient levels of block (<60%) measured experimentally.
LOOCV results for the 12 training drugs at 1–25× Cmax
are summarized in Figure 7A. As concentration increased,
prediction errors improved for some drugs and worsened for
others. Terfenadine’s prediction error was the highest of all
drugs at 1× Cmax (0.4545) but decreased to <0.01 at 4× Cmax
(blue diamonds). On the other hand, prediction errors for
chlorpromazine (blue circles), sotalol (red triangles), verapamil
(green triangles), cisapride (blue× s), and dofetilide (red squares)
all generally increased from 1 to 10× Cmax. Above 10× Cmax,
prediction errors for dofetilide and ranolazine (green crosses)
increased, while prediction errors for sotalol decreased. As a
result of these trends, both the mean and the standard deviation
of prediction errors were lowest at 1–4× Cmax (Figure 7A,
black points and error bars), near the concentrations for which
experimental data on all currents were available for the 12
training drugs.
TABLE 5 | Leave-one-out cross validation for TdP risk prediction at 1× Cmax.
Left-out drug Category P(0) P(1) P(2) Prediction error
1× Cmax Dofetilide 2 0 0.033 (0) 0.967 (1) 0.033 (0)
Bepridil 2 0 0 1 0
Sotalol 2 0 0.3475 (0) 0.6525 (1) 0.3475 (0)
Quinidine 2 0 0 1 0
Cisapride 1 0 1 0 0
Terfenadine 1 0 0.5455 (0) 0.4545 (1) 0.4545 (1)
Ondansetron 1 0 1 0 0
Chlorpromazine 1 0.1575 (1) 0.8425 (0) 0 0.1575 (1)
Verapamil 0 0.9995 (1) 0.0005 (0) 0 0.0005 (0)
Ranolazine 0 0.9215 (1) 0.0785 (0) 0 0.0785 (0)
Mexiletine 0 1 0 0 0
Diltiazem 0 1 0 0 0
10× Cmax Dofetilide 2 0.0373 (0) 0.0580 (0) 0.9047 (1) 0.1326 (0)
Bepridil 2 0 0 1 0
Sotalol 2 0 0.712 (0) 0.288 (1) 0.712 (0)
Quinidine 2 0 0 1 0
Cisapride 1 0 0.728 (1) 0.272 (0) 0.272 (0)
Terfenadine 1 0 1 0 0
Ondansetron 1 0 1 0 0
Chlorpromazine 1 0.9945 (1) 0.0055 (0) 0 0.9945 (1)
Verapamil 0 0.3075 (1) 0.6925 (0) 0 0.6925 (0)
Ranolazine 0 1 0 0 0
Mexiletine 0 1 0 0 0
Diltiazem 0 1 0 0 0
The TdP risk levels were assigned category values of 2 (High), 1 (Intermediate), and 0 (Low). A classifier was trained on 11 of 12 drugs and then used to predict the category probabilities
[P(x), where x is the category value] and to obtain an overall prediction error for the remaining drug (see section Cross Validation). Uncertainty model simulations were used for training
and prediction. For comparison, probabilities, and prediction errors from Dutta et al. (2017) are shown in parentheses when they differed from uncertainty results.
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FIGURE 7 | Cross validation of TdP risk stratification with uncertainty quantification. LOOCV was performed at each concentration to assess TdP risk stratification
performance. Prediction error for each drug was obtained by training on qNet distribution samples from all other drugs and calculating the mean classification error of
the test drug’s samples. (A) LOOCV at 1−25× Cmax. Markers show the prediction errors for each drug when it was “left out,” as indicated in the legend. Black points
and error bars are the mean + standard deviation (SD) of prediction errors at each concentration. High TdP-risk drugs are in red, Intermediate-risk drugs are in blue,
and Low-risk drugs are in green. (B) LOOCV at 1−4× Cmax was repeated with the drug effects for a particular ionic current removed. Black points are the mean
prediction errors from (A). Markers show the mean prediction errors that resulted when drug effects on the ionic current indicated in the legend were omitted from
simulations.
To explore the impact of different ionic currents on TdP risk
stratification, LOOCV was repeated for a set of simulations in
which drug effects on a particular ion channel were removed.
This analysis was limited to 1–4× Cmax in order to avoid
concentrations at which uncertainty was due primarily to the
lack of experimental data. When drug effects on INa, Ito, IKs, or
IK1 were removed, prediction errors were virtually unchanged
(Figure 7B). However, when drug effects on ICaL, INaL, or
IKr were removed, prediction errors increased dramatically,
indicating that TdP risk stratification of the 12 CiPA training
compounds depended primarily on the drug effects for these
three currents. Because most of the training compounds (other
than quinidine) did not block INa, Ito, IKs, or IK1 substantially at
1−4× Cmax, their resulting impact on TdP risk stratification was
expected to be minimal.
DISCUSSION
Although many potential sources of uncertainty exist within
the CiPA paradigm, the primary concern for the in silico
component is uncertainty related to in vitro measurements of
pharmacological effects on ionic currents. This study presents
methods for conducting UQ within the framework of the
CiPA in silico assay. Previously, Dutta et al. (2017) showed
that the metric qNet, derived from fixed-input AP simulations
incorporating multiple ion channel pharmacology, could be used
to stratify the CiPA training set of 12 compounds by relative
TdP risk. This study examined the impact of uncertainty in drug
effects on simulation predictions. Bootstrapping and Bayesian
inference were used to estimate the joint probability distributions
of drug parameters in order to quantify the variability in mean
drug effects. This variability was then propagated to a set
of uncertainty-input AP simulations to assess the robustness
of risk stratification with qNet. UQ revealed that some drug
effects were insufficiently constrained at higher concentrations
to be able to stratify TdP risk with high confidence. Near
therapeutic concentrations, however, TdP risk stratification was
robust to the uncertainty in drug effects. This study illustrates the
benefits of applying UQ under the CiPA paradigm, both during
model validation and when model-based predictions are used in
regulatory decision making.
UQ helped to identify challenges concerning model
calibration and parameter identification that will inform future
model development. Such issues are frequently encountered in
models of cardiac electrophysiology but are not often addressed
during model development (Fink and Noble, 2009; Shotwell and
Gray, 2016). In the Li et al. (2017) IKr Markov model, drug-hERG
binding kinetics was characterized by six parameters, but one
parameter (drug trapping rate, Kt) was fixed at a value of
3.5× 10−5 ms−1. UQ revealed that three of the remaining five
parameters (Kmax, EC50
n, and Vhalftrap) could not be precisely
estimated based on the available data. Although the current
model structure was designed to allow for both linear and
sigmoidal drug binding as well as drug trapping, this flexibility
comes at the expense of parameter identifiability and presents
difficulties for UQ. To address these issues, model recalibration
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and/or simplification may be warranted, as was done for a model
of INa inactivation in Pathmanathan et al. (2015).
On the other hand, for some drugs, the observed hERG block
kinetics could not be accurately captured by the IKr Markov
model. For instance, at 10 nM cisapride, hERG block developed
more slowly in the experimental traces than in fitted model, even
when uncertainty was considered (Figure S4B). This suggests that
alternative (and possibly more complex) model structures might
be needed to characterize certain drugs. Thus, the challenge for
CiPA is to define a one-size-fits-all model that is simple enough
to be estimable but still accurate enough to predict TdP risk.
The current approach attempts to strike an appropriate balance
between the two concerns, combining the flexible dynamic
representation of IKr block with a simplified pore-block approach
for other currents. The final assessment of the model will depend
on its validation with an additional 16 compounds, which will
determine its suitability for CiPA (Colatsky et al., 2016).
Many IC50-values could not be reliably estimated from
the current data, an issue raised previously by Johnstone
et al. (2016a). This occurred when fitted IC50-values were
well above the tested concentrations, resulting in high levels
of uncertainty in the upper concentration ranges simulated
by Li et al. (2017) and Dutta et al. (2017). The impact of
this uncertainty is illustrated in results for the High-risk drug
dofetilide, which is known to be a selective hERG blocker.
Because its hERG selectivity could not be confirmed above 3×
Cmax with the current dataset (see Figure 3D and Figures S12–
S15), uncertainty-input simulations of dofetilide above 10×Cmax
resulted in highly variable qNet-values, including very “safe”
values similar to Low-risk drugs (Figure 6B). Although the
impact of dofetilide on non-hERG currents is likely small, such
assumptions cannot be made for new compounds, particularly
if such currents and higher concentration ranges are deemed
relevant for TdP risk prediction. To avoid these assumptions,
in silico model predictions should be limited to concentrations
less than or equal to the highest tested experimentally, unless
the amount of drug block can be reliably extrapolated from
data at lower concentrations (generally, if >60% block is
achieved experimentally, see Figure 4). Thus, UQ highlights the
importance of obtaining the appropriate data for generating
reliable model predictions within the CiPA paradigm. For the
current training set, TdP risk prediction appeared to depend
solely on ICaL, INaL, and IKr data (Figure 7B), so this “60%
rule” may potentially only need apply to these three currents.
However, the importance of INa, Ito, IKs, and IK1 cannot be
discounted entirely because most of the training compounds
did not substantially affect these currents. Further sensitivity
analysis of qNet and testing with additional compounds may
provide insight into the importance of these currents for TdP risk
prediction.
Hierarchical UQ approaches may account for some of the
discrepancies between observed experimental variability and the
estimated variability of model outputs in the present study. For
example, at the highest bepridil concentration (300 nM), the
kinetics of IKr block in a few cells was noticeably faster than
that of other cells and the fitted bootstrap traces. Although it
is unlikely that any single method could capture all observed
variability, hierarchical approaches to quantify inter-individual
variabilitymay provide amore accurate representation of the true
physiological variability than do population-averaged approaches
(Pathmanathan et al., 2015). Recently, Johnstone et al. (2016a)
used a hierarchical statistical model to assess the inter-experiment
variability of drug block data from Crumb et al. (2016). Such
an approach could be explored in the future if complete dose-
response data for all ionic currents become available. In the
present study, however, the IC50 of most currents could not
be reliably estimated, so a further hierarchical analysis was not
warranted. For the Li et al. (2017) IKr Markov model, hierarchical
methods would be more experimentally and computationally
challenging. Experimentally, this would require obtaining hERG
block data for each cell at multiple concentrations in order
to estimate individual dose-dependent kinetics. However, due
to stability and time limitations associated with the current
experimental protocol, cells were only recorded at a single
concentration. The computational demands of estimating
hierarchical model parameters for dynamic models would also
be very high because of the need to integrate differential
equations. Addressing these difficulties may be unnecessary for
CiPA, however, if a population-averaged approach to UQ is
shown to provide sufficient information for robust TdP risk
prediction.
The UQ results presented in this study illustrate the need
to evaluate model predictions in the context of uncertainty.
Previously, Dutta et al. (2017) demonstrated that qNet could
separate the CiPA training drugs by TdP risk better than
metrics based on AP or Ca2+ transient morphology. In addition,
the mean LOOCV prediction error of qNet was lower when
drugs were simulated at 10× and 20× Cmax than at 1× Cmax,
suggesting that higher concentrations could provide better risk
separation. However, this assessment was based only on fixed-
input simulations. When uncertainty inputs were used to classify
drugs, mean LOOCV prediction error was lowest at 1–4×
Cmax and worsened as concentration increased above 4× Cmax
(Figure 7A). In part, the differences in LOOCV results for
fixed vs. uncertainty inputs were due to the high uncertainty
in qNet for drugs such as, dofetilide and verapamil above 4×
Cmax (Figure 6C). However, these differences also arose because
when uncertainty was low, classification with qNet probability
distributions was more robust than with fixed qNet-values,
which improved the mean LOOCV prediction error at 1× Cmax
(Table 5). UQ also provided an indication of the degree to which
drugs could be separated, so LOOCV was more sensitive to
subtle changes in qNet. Risk stratification of the training drugs
at >4× Cmax may be improved if additional in vitro data are
obtained at higher concentrations and incorporated into the
model. However, it is important to keep in mind that the CiPA-
assigned TdP risk levels for the 12 training and 16 validation
compounds are not absolute; these relative risks are mainly based
on years of clinical evidence and expert opinion rather than a
quantitative measure of real-world data. Effort is ongoing within
the CiPA framework to develop more objective and quantitative
TdP risk categorization systems based on postmarket data, which
will help to refine the model and metric for more accurate TdP
risk assessment.
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This study did not address the issue of model uncertainty
related to physiological variability because the focus of CiPA is on
drug screening and obtaining an estimate of proarrhythmic risk
that can be used to assess overall drug safety, not on predicting
risk in specific individuals or subpopulations. However, this is
an important topic for many safety pharmacology applications
involving mathematical modeling. In pharmacokinetics, non-
linear mixed effects (NLME) models have routinely been applied
to quantify intersubject variability (Fitzmaurice et al., 2008).
However, methods for quantifying physiological variability in
more complex cardiac electrophysiology models are not well-
established. One approach has been to use a “population”
of in silico cardiac cell models, generated by randomly
varying model parameters, to explore mechanisms underlying
physiological variability and to predict the resulting variability in
drug responses, such as, hERG block-induced changes in APD
(Sarkar and Sobie, 2011; Britton et al., 2013). The aim of UQ
is to estimate model parameters within a statistical framework
and then to give probabilistic predictions. Pathmanathan et al.
(2015) used data from 10 to 16 cells and NLME modeling to
perform a thorough UQ analysis of a single model parameter,
steady-state INa inactivation. But applying similar approaches to
whole cell models, which typically have dozens of parameters,
would require large amounts of data and, most likely, simpler
models, as discussed by Pathmanathan et al. (2015). Nevertheless,
such studies on physiological variability can be considered in
complement with the results in this study concerning UQ of
drug effects, providing insight into how multiple sources of
uncertainty may impact variability in drug responses.
One additional issue that was not explored in this study was
the effect of the number of experimental repeats on parameter
uncertainty. For the manual patch clamp data used in this
study, 4–10 repeats were obtained per drug concentration for
the hERG experiments, and 3–4 repeats were obtained for non-
hERG experiments. Thus, based on the current dataset, 3–4
experimental repeats appeared sufficient to constrain the model
parameters for TdP risk prediction. However, data obtained from
multiple labs or using automated, high-throughput systems can
be much more variable, and more experimental repeats may be
needed to accurately estimate the mean drug effect with these
types of data (Elkins et al., 2013). These issues may be addressed
in the future CiPA in silico validation phase.
In summary, risk stratification of the CiPA training drugs
with the currently available data was most reliable near the
maximum clinical concentration. This was because most of the
in vitro experiments were designed around known therapeutic
concentrations that often did not block the major ionic currents,
and measurements at significantly higher concentrations were
not consistently obtained for all drugs. The lack of experimental
data produced a large degree of uncertainty in drug effects,
which negatively impacted the ability to distinguish between
drugs of different TdP risk at higher concentrations. Hence, our
findings suggest that for new compounds, the CiPA in silico
assay will require in vitro measurements at much higher drug
concentrations that can achieve significant ionic current block
if the model is expected to provide TdP risk predictions with
high confidence. Whether this will be necessary for all seven
ion channels that have been suggested as part of CiPA, however,
remains to be determined.
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